Shaping the “hot” immunogenic tumor microenvironment by nanoparticles co‐delivering oncolytic peptide and TGF‐β1 siRNA for boosting checkpoint blockade therapy
Authors:
Open Access
- 11 August 2022
- journal article
- research article
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 8 (5)
Abstract
Induction of potent immune responses toward tumors remains challenging in cancer immunotherapy, in which it only showed benefits in a minority of patients with “hot” tumors, which possess pre‐existing effector immune cells within the tumor. In this study, we proposed a nanoparticle‐based strategy to fire up the “cold” tumor by upregulating the components associated with T and NK cell recruitment and activation and suppressing TGF‐β1 secretion by tumor cells. Specifically, LTX‐315, a first‐in‐class oncolytic cationic peptide, and TGF‐β1 siRNA were co‐entrapped in a polymer‐lipid hybrid nanoparticle comprising PLGA, DSPE‐mPEG, and DSPE‐PEG‐conjugated with cRGD peptide (LTX/siR‐NPs). The LTX/siR‐NPs showed significant inhibition of TGF‐β1 expression, induction of type I interferon release, and triggering immunogenic cell death (ICD) in treated tumor cells, indicated via the increased levels of danger molecules, an in vitro setting. The in vivo data showed that the LTX/siR‐NPs could effectively protect the LTX‐315 peptide from degradation in serum, which highly accumulated in tumor tissue. Consequently, the LTX/siR‐NPs robustly suppressed TGF‐β1 production by tumor cells and created an immunologically active tumor with high infiltration of antitumor effector immune cells. As a result, the combination of LTX/siR‐NP treatment with NKG2A checkpoint inhibitor therapy remarkably increased numbers of CD8+NKG2D+ and NK1.1+NKG2D+ within tumor masses, and importantly, inhibited the tumor growth and prolonged survival rate of treated mice. Taken together, this study suggests the potential of the LTX/siR‐NPs for inflaming the “cold” tumor for potentiating the efficacy of cancer immunotherapy.Keywords
Funding Information
- National Research Foundation of Korea (2022R1A5A2018865, NRF‐2021R1A2C3009556)
This publication has 45 references indexed in Scilit:
- Targeting the TGFβ pathway for cancer therapyPharmacology & Therapeutics, 2015
- Role of TGFβ in regulation of the tumor microenvironment and drug delivery (Review)International Journal of Oncology, 2015
- Cyclic RGD-Linked Polymeric Micelles for Targeted Delivery of Platinum Anticancer Drugs to Glioblastoma through the Blood–Brain Tumor BarrierACS Nano, 2013
- Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapyNature Materials, 2012
- Tissue-Penetrating Delivery of Compounds and Nanoparticles into TumorsCancer Cell, 2009
- Transforming growth factor-β in breast cancer: too much, too lateBreast Cancer Research, 2009
- Integrin αvβ3‐targeted cancer therapyDrug Development Research, 2008
- NKG2D ligands: key targets of the immune responseTrends in Immunology, 2008
- Transforming Growth Factor-β and the Immune Response to Malignant DiseaseClinical Cancer Research, 2007
- Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatmentExpert Opinion on Investigational Drugs, 2006